ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ani Pharmaceuticals, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.957 Good morning, everyone, and welcome to today's A&I Pharmaceuticals third quarter 2025 00:00:04.957 -- 00:00:08.881 earnings results call. Please note this call is being recorded. 00:00:08.881 -- 00:00:12.826 After the speaker's opening remarks, there will be a question and answer session. 00:00:12.826 -- 00:00:16.991 If you would like to ask a question during this time, simply press star, then the number 00:00:16.991 -- 00:00:20.575 one on your telephone. We ask that you please limit yourself to one question. 00:00:20.575 -- 00:00:25.141 If you would like to withdraw your question, please press star, then the number two. 00:00:25.141 -- 00:00:27.684 It is now my pleasure to turn the conference over to Ms. 00:00:27.684 -- 00:00:32.166 Courtney Mogerly, Investor Relations. Please go ahead, ma'am. 00:00:32.269 -- 00:00:37.554 Thank you, operator. Welcome to ANI Pharmaceuticals Q3 2025 Earnings 00:00:37.554 -- 00:00:42.099 Results Call. This is Courtney Mogerly, Investor Relations for ANI. 00:00:42.099 -- 00:00:47.205 With me on today's call are Nikhil Awani, President and Chief Executive Officer, 00:00:47.205 -- 00:00:52.590 Stephen Carey, Chief Financial Officer, and Chris Mutz, Senior Vice President 00:00:52.590 -- 00:00:57.607 and Head of ANI's Rare Disease Business. You can also access the webcast of 00:00:57.607 -- 00:01:03.356 this call through the investor section of the ANI website at anifarmaceuticals.com. 00:01:05.064 -- 00:01:09.274 Before we get started, I would like to remind everyone that any statements made on today's 00:01:09.274 -- 00:01:14.872 conference call that express a belief, expectation, projection, forecast, 00:01:14.872 -- 00:01:20.659 Anticipation or intent regarding future events and the company's future p...